Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: No Evidence of Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of 9cUAB30 in Healthy Participants

NCT00896974
View directory record Official record
Conditions
No Evidence of Disease
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Retinoid 9cUAB30
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

NCT00020254
View directory record Official record
Conditions
Prostate Cancer
Interventions
aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, nilutamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
Interventions
letrozole, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Tucson, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02099136
View directory record Official record
Conditions
No Evidence of Disease
Interventions
UV Light Therapy, Placebo, Celecoxib, Biopsy, Imaging Biomarker Analysis
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

NCT07030686
View directory record Official record
Conditions
Survivorship, Recurrent, Recurrence, Cancer, Remission
Interventions
Exercise
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

NCT01394679
View directory record Official record
Conditions
Lung Cancer
Interventions
(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose), 18 F FDG followed by PET/CT imaging
Drug
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Garlic Supplements on Opioids in Healthy Volunteers

NCT00499460
View directory record Official record
Conditions
Healthy, No Evidence of Disease
Interventions
garlic powder tablets, oxycodone
Dietary Supplement · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 25, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants

NCT02154984
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Obesity
Interventions
behavioral dietary intervention, telephone-based intervention, laboratory biomarker analysis
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities

NCT02100254
View directory record Official record
Conditions
Colorectal Cancer, Healthy, no Evidence of Disease
Interventions
behavioral intervention
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Resveratrol in Healthy Adult Participants

NCT00721877
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
resveratrol, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women

NCT00513916
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
soy isoflavones
Dietary Supplement
Lead sponsor
University of Hawaii Cancer Research Center
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

NCT01230346
View directory record Official record
Conditions
No Evidence of Disease, BRCA1 Syndrome, BRCA2 Syndrome, Hereditary Female Breast Carcinoma, Hereditary Ovarian Carcinoma
Interventions
questionnaire administration, survey administration, counseling intervention, educational intervention
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
493 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

NCT01999881
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis
Behavioral · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Results available

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

NCT03388619
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions
Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT
Radiation · Diagnostic Test · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

NCT00896636
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
Random fine need aspiration (rFNA), Mammogram
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

NCT02780401
View directory record Official record
Conditions
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 9:10 AM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

NCT05642195
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Interventions
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of a Smart Growth Community's Effect on Prevention of Obesity in Middle-, Moderately Low- and Low-Income Families

NCT00986011
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Obesity, Weight Changes
Interventions
questionnaire administration, study of socioeconomic and demographic variables, survey administration, study of high risk factors
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 25, 2026, 9:10 AM EDT
Active, not recruiting Phase 3 Interventional

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557
View directory record Official record
Conditions
Breast Cancer, Early Breast Cancer
Interventions
Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
111
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

NCT00489372
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
Se-methyl-seleno-L-cysteine, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 25, 2026, 9:10 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer

NCT01259076
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
magnetic resonance imaging, digital mammography, conventional surgery
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 25, 2026, 9:10 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 25, 2026, 9:10 AM EDT